Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions—United States, 2020–2022

MLA

Anna Bratcher, et al. “Anti-Nucleocapsid SARS-CoV-2 Antibody Seroprevalence in Previously Infected Persons with Immunocompromising Conditions—United States, 2020–2022.” PLoS ONE, vol. 20, no. 1, Jan. 2025. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.f1fa01a9687d4a0db64aec9d31810a9e&authtype=sso&custid=ns315887.

APA

Anna Bratcher, Jefferson M. Jones, William A. Meyer, Rehan Waheed, Huda Yazgi, Aaron Harris, Adi V. Gundlapalli, & Kristie E. N. Clarke. (2025). Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions—United States, 2020–2022. PLoS ONE, 20(1).

Chicago

Anna Bratcher, Jefferson M. Jones, William A. Meyer, Rehan Waheed, Huda Yazgi, Aaron Harris, Adi V. Gundlapalli, and Kristie E. N. Clarke. 2025. “Anti-Nucleocapsid SARS-CoV-2 Antibody Seroprevalence in Previously Infected Persons with Immunocompromising Conditions—United States, 2020–2022.” PLoS ONE 20 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.f1fa01a9687d4a0db64aec9d31810a9e&authtype=sso&custid=ns315887.